AI Article Synopsis
- This study investigates outcomes for men with radiation-recurrent prostate cancer who underwent salvage radical prostatectomy (SRP), focusing on predictors of biochemical recurrence (BCR), metastasis, and cancer-specific death.
- The analysis involved 404 patients and found that after a median follow-up of 4.4 years, about 37% were free from BCR, 77% from metastasis, and 83% were alive without cancer-specific death at 10 years.
- Key predictors for BCR and metastasis included pre-SRP PSA levels and Gleason scores, with lymph node involvement also indicating a higher risk for metastasis.
Article Abstract
Background: Oncologic outcomes in men with radiation-recurrent prostate cancer (PCa) treated with salvage radical prostatectomy (SRP) are poorly defined.
Objective: To identify predictors of biochemical recurrence (BCR), metastasis, and death following SRP to help select patients who may benefit from SRP.
Design, Setting, And Participants: This is a retrospective, international, multi-institutional cohort analysis. There was a median follow-up of 4.4 yr following SRP performed on 404 men with radiation-recurrent PCa from 1985 to 2009 in tertiary centers.
Intervention: Open SRP.
Measurements: BCR after SRP was defined as a serum prostate-specific antigen (PSA) ≥ 0.1 or ≥ 0.2 ng/ml (depending on the institution). Secondary end points included progression to metastasis and cancer-specific death.
Results And Limitations: Median age at SRP was 65 yr of age, and median pre-SRP PSA was 4.5 ng/ml. Following SRP, 195 patients experienced BCR, 64 developed metastases, and 40 died from PCa. At 10 yr after SRP, BCR-free survival, metastasis-free survival, and cancer-specific survival (CSS) probabilities were 37% (95% confidence interval [CI], 31-43), 77% (95% CI, 71-82), and 83% (95% CI, 76-88), respectively. On preoperative multivariable analysis, pre-SRP PSA and Gleason score at postradiation prostate biopsy predicted BCR (p = 0.022; global p < 0.001) and metastasis (p = 0.022; global p < 0.001). On postoperative multivariable analysis, pre-SRP PSA and pathologic Gleason score at SRP predicted BCR (p = 0.014; global p < 0.001) and metastasis (p < 0.001; global p < 0.001). Lymph node involvement (LNI) also predicted metastasis (p = 0.017). The main limitations of this study are its retrospective design and the follow-up period.
Conclusions: In a select group of patients who underwent SRP for radiation-recurrent PCa, freedom from clinical metastasis was observed in >75% of patients 10 yr after surgery. Patients with lower pre-SRP PSA levels and lower postradiation prostate biopsy Gleason score have the highest probability of cure from SRP.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124574 | PMC |
| http://dx.doi.org/10.1016/j.eururo.2011.03.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Salvage Radical Prostatectomy for Radio-Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response.
Curr Oncol
July 2021
Department of Urology, Medical University of Vienna, 1090 Vienna, Austria.
A valid treatment option for recurrence after definite radiotherapy (RT) for localized prostate cancer (PC) is salvage radical prostatectomy (SRP). However, data on SRP are scarce, possibly resulting in an underutilization. A systematic review was performed using MEDLINE (Pubmed), Embase, and Web of Science databases including studies published between January 1980 and April 2020.
View Article and Find Full Text PDFSalvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.
Eur Urol
August 2011
Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Article Synopsis
- This study investigates outcomes for men with radiation-recurrent prostate cancer who underwent salvage radical prostatectomy (SRP), focusing on predictors of biochemical recurrence (BCR), metastasis, and cancer-specific death.
- The analysis involved 404 patients and found that after a median follow-up of 4.4 years, about 37% were free from BCR, 77% from metastasis, and 83% were alive without cancer-specific death at 10 years.
- Key predictors for BCR and metastasis included pre-SRP PSA levels and Gleason scores, with lymph node involvement also indicating a higher risk for metastasis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!